A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Brimonidine (Primary)
- Indications Dry age-related macular degeneration
- Focus Therapeutic Use
- Acronyms BEACON
- Sponsors Allergan
- 10 Oct 2016 According to Allergan media release, new data will be presented at the 2016 American Academy of Ophthalmology Annual Meeting in Chicago.
- 20 Sep 2016 Planned End Date changed from 1 Feb 2019 to 1 Mar 2019.
- 20 Sep 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Sep 2018.